Similarly, Wang and co‐workers obtained CMNs overexpressing PD‐L1 through genetic engineering and coated them on PLGA NPs to prepare mesenchymal stem cell (MSC)–PD‐L1+ NPs used to reduce immune‐related adverse events induced by ICIs.[79] CAR‐T cell therapy has achieved significant clinical efficacy in leukemia and other hematological cancers. This evidence concerns the gene CD274 and leukemia.